SecuraBio

Quick facts

Phase 3 pipeline

• IPI-145 · Oncology
  IPI-145 is a dual inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma isoforms that suppresses B-cell and T-cell signaling to reduce malignant cell proliferation and survival.

Phase 2 pipeline

• IPI-145, a PI3K Inhibitor
• PI3K inhibitor

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• SecuraBio portfolio CI brief
• SecuraBio pipeline updates RSS